Published in Anticancer Res on May 19, 1992
The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell (1993) 4.33
Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO J (1995) 2.38
Reevaluating cathepsin D as a biomarker for breast cancer: serum activity levels versus histopathology. Cancer Biol Ther (2010) 1.55
Cathepsin D expression levels in nongynecological solid tumors: clinical and therapeutic implications. Clin Exp Metastasis (2004) 1.00
Expressions of chromogranin A and cathepsin D in human primary hepatocellular carcinoma. World J Gastroenterol (2000) 0.91
Relaxin enhances the oncogenic potential of human thyroid carcinoma cells. Am J Pathol (2006) 0.87
Western immunoblotting and enzymatic activity analysis of cathepsin D in human breast cancer cell lines of different invasive potential. Regulation by 17beta-estradiol, tamoxifen and ICI 182,780. Clin Exp Metastasis (1997) 0.81
Expression of cathepsin D and E-cadherin in primary laryngeal cancers correlation with neck lymph node involvement. J Cancer Res Clin Oncol (2011) 0.81
CORRELATIONSHIP OF CATHEPSIN D AND TOPOISOMERASE II ALPHA WITH NUCLEAR GRADING IN BREAST CANCERS. Med J Armed Forces India (2011) 0.75
Cathepsin B and Cathepsin D Expression in Follicular Adenomas and Carcinomas of the Thyroid Gland. Endocr Pathol (1997) 0.75
Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol (2002) 1.74
Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. Cancer (1994) 1.55
Ras family genes: an interesting link between cell cycle and cancer. J Cell Physiol (2002) 1.29
Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. Ann Oncol (2006) 1.18
On the possible causes of the release of material absorbing at 260 m-mu by streptomycin treated E. coli cells (K 12 and B). J Antibiot (Tokyo) (1967) 1.08
[Release of nucleotides and integrity of the bacterial membrane (E. coli K 12)]. Antibiotica (1966) 1.06
Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann Oncol (2005) 1.05
Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers. Ann Oncol (2006) 1.03
Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. J Clin Oncol (1988) 1.01
Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features. Ann Oncol (2007) 0.95
Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients. Ann Oncol (2005) 0.95
DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study. J Cancer Res Clin Oncol (2002) 0.94
Lacidipine and josamycin: two new multidrug resistance modulators. Anticancer Res (1995) 0.94
Cathepsin D, B and L circulating levels as prognostic markers of malignant progression. Anticancer Res (1996) 0.93
Lysosomal cathepsins B and L and Stefin A blood levels in patients with hepatocellular carcinoma and/or liver cirrhosis: potential clinical implications. Oncology (1997) 0.92
Acute pain syndrome at tumour site in neoplastic patients treated with vinorelbine: report of unusual toxicity. Eur J Cancer (1994) 0.91
Single agent paclitaxel in advanced squamous cell head and neck carcinoma. Eur J Cancer (1996) 0.90
Cathepsin D serum mass concentrations in patients with hepatocellular carcinoma and/or liver cirrhosis. Eur J Clin Chem Clin Biochem (1996) 0.87
Prognostic significance of DNA ploidy, S-phase fraction, and tissue levels of aspartic, cysteine, and serine proteases in operable gastric carcinoma. Clin Cancer Res (2000) 0.86
Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis. Ann Oncol (2007) 0.86
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study. Oncol Rep (2010) 0.85
Thymidylate synthase gene promoter polymorphisms are associated with TSmRNA expressions but not with microsatellite instability in colorectal cancer. Anticancer Res (2005) 0.84
Cardiac peroxisomal enzymes and starvation. Free Radic Res Commun (1989) 0.83
A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in patients with advanced carcinoma. J Chemother (1993) 0.83
Emotional expression and coping style in female breast cancer. Ann Oncol (2007) 0.83
Lysosomal aspartic and cysteine proteinases serum levels in patients with pancreatic cancer or pancreatitis. Pancreas (1997) 0.83
Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: a phase II study of the Southern Italy Oncology Group (GOIM). Anticancer Drugs (1997) 0.83
The in vitro effect of recombinant erythropoietin on cisdiamminodichloroplatinum-induced inhibition of murine erythroid stem cells. Anticancer Res (1991) 0.82
Mitomycin "C" and vinorelbine as second line chemotherapy for metastatic breast carcinoma. Tumori (1994) 0.81
The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis. Cell Death Differ (1998) 0.81
Repair kinetics of DNA, RNA and proteins in the tissues of mice treated with doxorubicin. Arzneimittelforschung (1979) 0.81
Aurora-A overexpression as an early marker of reflux-related columnar mucosa and Barrett's oesophagus. Ann Oncol (2007) 0.81
Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients. Ann Oncol (2006) 0.81
Thymidylate synthase level and DNA-ploidy pattern as possible prognostic factors in human colorectal cancer: a preliminary study. Anticancer Res (1995) 0.81
Analysis of the pharmacokinetic characteristics, pharmacological and chemotherapeutic activity of 14-Hydroxy-daunomycin (Adriamycin), a new drug endowed with an antitumour activity. Arzneimittelforschung (1971) 0.81
Management and treatment of triple-negative breast cancer patients from the NEMESI study: an Italian experience. Eur J Cancer (2011) 0.80
A prospective randomized trial of thymopentin versus granulocyte--colony stimulating factor with or without thymopentin in the prevention of febrile episodes in cancer patients undergoing highly cytotoxic chemotherapy. Anticancer Res (1994) 0.80
Haemopoietic effects of 7 alpha, 17 beta dimethyltestosterone. Pharmacol Res Commun (1979) 0.80
Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer. Br J Cancer (1996) 0.79
Lysosomal alterations in heart and liver of mice treated with doxorubicin. Cancer Chemother Pharmacol (1985) 0.79
A case of Guillain-Barré syndrome in a patient with non small cell lung cancer treated with chemotherapy. J Chemother (2006) 0.79
The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers. J Chemother (2005) 0.79
Primary extranodal non-Hodgkin lymphomas of the uterus and the breast: report of three cases. Eur J Surg Oncol (1995) 0.79
Oral tegafur in the treatment of gastrointestinal tract cancers: a phase II study. Br J Cancer (1990) 0.79
The in vitro effect of the antineoplastic agent bryostatin 4 on human hematopoietic progenitor cells. Haematologica (1989) 0.79
4843delC of the BRCA1 gene is a possible founder mutation in Southern Italy (Sicily). Ann Oncol (2007) 0.79
A pilot study of vinorelbine on a weekly schedule in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer (1993) 0.79
A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma. Int J Gynecol Cancer (2006) 0.79
5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomised phase II study of the Southern Italy Oncology Group. Ann Oncol (2000) 0.79
Levo folinic acid and 5-fluorouracil plus high dose epidoxorubicin as first line treatment for metastatic breast carcinoma. Anticancer Res (1993) 0.78
Difference in Ki67 and thymidylate synthase expression in primary tumour compared with metastatic nodes in breast cancer patients. Nucleosides Nucleotides Nucleic Acids (2006) 0.78
Cisplatinum in combination with 5-fluorouracil and citrovorum factor in the treatment of advanced colorectal carcinoma. Cancer Invest (1992) 0.78
Treatment of stage III-IV non-small-cell lung carcinoma with vinorelbine in combination with ifosfamide plus MESNA: a study by the Southern Italy Oncology Group (GOIM). Am J Clin Oncol (1996) 0.78
Failure of detection of the tyrosine to histidine substitution at the residue 33 of thymidylate synthase in human colorectal cancer. A preliminary study. Anticancer Res (2001) 0.78
FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Ann Oncol (2005) 0.78
The role of thymidylate synthase levels in the prognosis and the treatment of patients with colorectal cancer. Anticancer Res (1998) 0.78
Hereditary common cancers: molecular and clinical genetics. Anticancer Res (2001) 0.78
5-Fluorouracil plus interferon alpha-2a compared to 5-fluorouracil alone in the treatment of advanced colon carcinoma: a multicentric randomized study. J Cancer Res Clin Oncol (1998) 0.78
Cis-diamminodichloroplatinum plus a 5-day continuous infusion of 5-fluorouracil in the treatment of locally recurrent and metastatic head and neck cancer patients. J Cancer Res Clin Oncol (1989) 0.78
Escalating doses of mitoxantrone with granulocyte colony-stimulating factor (G-CSF) rescue plus 5-fluorouracil and high-dose levofolinic acid in metastatic breast cancer. Eur J Cancer (1994) 0.78
Pepstatins: aspartic proteinase inhibitors having potential therapeutic applications. Med Res Rev (1993) 0.78
Antimetastatic activity of adriamycin in combinations with proteinase inhibitors in mice. Anticancer Res (1990) 0.78
High-dose folinic acid and 5-fluorouracil plus cisplatin on a weekly schedule in the treatment of advanced cancer of the head and neck. J Cancer Res Clin Oncol (1992) 0.78
Results of the combination of cisplatin, adriamycin and cyclophosphamide in the treatment of ovarian carcinoma. Eur J Gynaecol Oncol (1993) 0.77
Analysis of human dysplastic haematopoiesis in long-term bone marrow culture. Blut (1989) 0.77
Effect of buthionine sulfoximine on the sensitivity to doxorubicin of parent and MDR tumor cell lines. J Chemother (1994) 0.77
[Clinical guidelines for the management of gastrointestinal stromal tumors]. Clin Ter (2006) 0.77
Intracavitary beta-interferon for the management of pleural and/or abdominal effusions in patients with advanced cancer refractory to chemotherapy. In Vivo (1992) 0.77
Kinetics of in vivo inhibition of tissue cathepsin D by pepstatin A. Int J Biochem (1988) 0.77
Cathepsin D content in colorectal cancer. Correlation with cathepsin D activity and other biological parameters: a preliminary report. Oncology (1995) 0.77
Chemotherapy in head and neck cancer (I): Management of recurrent or metastatic disease. J Chemother (1992) 0.77
In vitro generation of cytotoxic T lymphocytes against HLA-A2.1-restricted peptides derived from human thymidylate synthase. J Chemother (2001) 0.77